Washington University has a long history of research in the area of imaging. Investigations on the clinical application of the first computed tomography scanner were carried out at Washington University and positron emission tomography was initially developed here. The Oncologic Imaging Program emphasizes the developmental of novel imaging agents for nuclear imaging, MR imaging and optical imaging, as well as the application of a variety of imaging techniques to oncologic problems. The Program's research is focused in the following areas: (1) the development of new imaging agents to assess tumor therapy, 92) the investigation of agents designed to monitor multi-drug resistant modulators, (3) the development of new techniques in the area of molecular imaging, (4) the development of agents initially designed for oncologic imaging and extending their application to therapy with unsealed sources, and (5) the application for modern imaging techniques for the evaluation and planning of radiation treatment. Several research questionnaires are common to all of these areas. A major effort is being made in developing co-registration techniques for the various imaging modalities that can be utilized in small animal models of cancer, large animal imaging as well as human imaging. The Oncologic Imaging Program has the goal of expanding collaboration on the application of imaging techniques to answer specific questions in the other Programs. The Program is applying its expertise in small animal imaging to collaborations with the basic science Programs as well as translating basic science investigation to the Clinical and Translational Research Program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
1P30CA091842-01
Application #
6500123
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
2001-08-02
Project End
2004-06-30
Budget Start
Budget End
Support Year
1
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Washington University
Department
Type
DUNS #
062761671
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Salloum, Naji C; Buchalter, Erica Lf; Chanani, Swati et al. (2018) From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation. Pharmacogenomics 19:861-871
Aliev, Fazil; Salvatore, Jessica E; Agrawal, Arpana et al. (2018) A Brief Critique of the TATES Procedure. Behav Genet 48:155-167
Mills, Jason C; Samuelson, Linda C (2018) Past Questions and Current Understanding About Gastric Cancer. Gastroenterology 155:939-944
Shepherd, Andrew J; Copits, Bryan A; Mickle, Aaron D et al. (2018) Angiotensin II Triggers Peripheral Macrophage-to-Sensory Neuron Redox Crosstalk to Elicit Pain. J Neurosci 38:7032-7057
Dehdashti, Farrokh; Wu, Ningying; Bose, Ron et al. (2018) Evaluation of [89Zr]trastuzumab-PET/CT in differentiating HER2-positive from HER2-negative breast cancer. Breast Cancer Res Treat 169:523-530
Donabedian, Patrick L; Kossatz, Susanne; Engelbach, John A et al. (2018) Discriminating radiation injury from recurrent tumor with [18F]PARPi and amino acid PET in mouse models. EJNMMI Res 8:59
Groves, Andrew P; Gettinger, Katie; Druley, Todd E et al. (2018) Special Therapy and Psychosocial Needs Identified in a Multidisciplinary Cancer Predisposition Syndrome Clinic. J Pediatr Hematol Oncol :
Andley, Usha P; Tycksen, Eric; McGlasson-Naumann, Brittney N et al. (2018) Probing the changes in gene expression due to ?-crystallin mutations in mouse models of hereditary human cataract. PLoS One 13:e0190817
Sáenz, José B; Mills, Jason C (2018) Acid and the basis for cellular plasticity and reprogramming in gastric repair and cancer. Nat Rev Gastroenterol Hepatol 15:257-273
Miller, Christopher A; Tricarico, Christopher; Skidmore, Zachary L et al. (2018) A case of acute myeloid leukemia with promyelocytic features characterized by expression of a novel RARG-CPSF6 fusion. Blood Adv 2:1295-1299

Showing the most recent 10 out of 1244 publications